Circulating cell-free DNA, SLC5A8 and SLC26A4 hypermethylation, BRAFV600E: A non-invasive tool panel for early detection of thyroid cancer

Biomedicine and Pharmacotherapy

Volumn 67, Issue 8, 2013, Pages 723-730

  Zane, Mariangela ^a   Agostini, Marco ^a,b,c   Enzo, Maria Vittoria ^a   Casal Ide, Eric ^a   Del Bianco, Paola ^d   Torresan, Francesca ^a   Merante Boschin, Isabella ^a   Pennelli, Gianmaria ^a   Saccani, Andrea ^e   Rubello, Domenico ^f   Nitti, Donato ^a   Pelizzo, Maria Rosa ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^c Fondazione Istituto di Ricerca Pediatrica Città della Speranza   (Italy)

^d VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^e Euroclone Spa   (Italy)

^f Santa Maria della Misericordia Hospital   (Italy)

Author keywords

BRAF; Cell free DNA; Early diagnosis; Methylation; Thyroid cancers

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; DNA; MEMBRANE PROTEIN; PENDRIN; SLC5A8 PROTEIN; UNCLASSIFIED DRUG;

ADULT; ANAPLASTIC THYROID CANCER; ARTICLE; BLOOD ANALYSIS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; DNA METHYLATION; EARLY DIAGNOSIS; FEMALE; GENE MUTATION; HISTOLOGY; HUMAN; HUMAN TISSUE; LOBECTOMY; LYMPH NODE DISSECTION; MALE; NON INVASIVE MEASUREMENT; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; THYROID ADENOMA; THYROID CANCER; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID FUNCTION; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY;

BRAF; CELL-FREE-DNA; EARLY DIAGNOSIS; METHYLATION; THYROID CANCERS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CATION TRANSPORT PROTEINS; DNA; EARLY DIAGNOSIS; FEMALE; HUMANS; MALE; METHYLATION; MIDDLE AGED; PILOT PROJECTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; SENSITIVITY AND SPECIFICITY; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; THYROID NEOPLASMS; YOUNG ADULT;

EID: 84887611777     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2013.06.007     Document Type: Article

References (43)

1. Lise M., Franceschi S., Buzzoni C., et al. Changes in the incidence of thyroid cancer between 1991 and 2005 in Italy: a geographical analysis. Thyroid 2012, 22:27-34.
2. Nikiforov Y.E. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med 2011, 135:569-577.
3. Agostini M., Pucciarelli S., Enzo M.V., et al. Circulating cell-free DNA: a promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiotherapy. Ann Surg Oncol 2011, 18:2461-2468.
4. Anker P., Lyautey J., Lederrey C., Stroun M. Circulating nucleic acids in plasma or serum. Clin Chim Acta 2001, 313:143-146.
5. De Mattos-Arruda L., Olmos D., Tabernero J. Prognostic and predictive roles for circulating biomarkers in gastrointestinal cancer. Future Oncol 2011, 7:1385-1397.
6. Alix-Panabieres C., Schwarzenbach H., Pantel K. Circulating tumor cells and circulating tumor DNA. Annu Rev Med 2012, 63:199-215.
7. Taback B., Hoon D.S. Circulating nucleic acids and proteomics of plasma/serum: clinical utility. Ann N Y Acad Sci 2004, 1022:1-8.
8. Taback B., Hoon D.S. Circulating nucleic acids in plasma and serum: past, present and future. Curr Opin Mol Ther 2004, 6:273-278.
9. Fujimoto A., O'Day S.J., Taback B., Elashoff D., Hoon D.S. Allelic imbalance on 12q22-23 in serum circulating DNA of melanoma patients predicts disease outcome. Cancer Res 2004, 64:4085-4088.
10. Jung K., Fleischhacker M., Rabien A. Cell-free DNA in the blood as a solid tumor biomarker-a critical appraisal of the literature. Clin Chim Acta 2010, 411:1611-1624.
11. Gormally E., Caboux E., Vineis P., Hainaut P. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat Res 2007, 635:105-117.
12. Jahr S., Hentze H., Englisch S., et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001, 61:1659-1665.
13. Giacona M.B., Ruben G.C., Iczkowski K.A., Roos T.B., Porter D.M., Sorenson G.D. Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls. Pancreas 1998, 17:89-97.
14. Deligezer U., Eralp Y., Akisik E., et al. Size distribution of circulating cell-free DNA in sera of breast cancer patients in the course of adjuvant chemotherapy. Clin Chem Lab Med 2008, 46:311-317.
15. Taback B., O'Day S.J., Boasberg P.D., et al. Circulating DNA microsatellites: molecular determinants of response to biochemotherapy in patients with metastatic melanoma. J Natl Cancer Inst 2004, 96:152-156.
16. Umetani N., Giuliano A.E., Hiramatsu S.H., et al. Prediction of breast tumor progression by integrity of free circulating DNA in serum. J Clin Oncol 2006, 24:4270-4276.
17. Jiang W.W., Zahurak M., Goldenberg D., et al. Increased plasma DNA integrity index in head and neck cancer patients. Int J Cancer 2006, 19:2673-2676.
18. Pinzani P., Salvianti F., Zaccara S., et al. Circulating cell-free DNA in plasma of melanoma patients: qualitative and quantitative considerations. Clin Chim Acta 2011, 412:2141-2145.
19. Umetani N., Kim J., Hiramatsu S., et al. Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats. Clin Chem 2006, 52:1062-1069.
20. Kohler C., Barekati Z., Radpour R., Zhong X.Y. Cell-free DNA in the circulation as a potential cancer biomarker. Anticancer Res 2011, 31:2623-2628.
21. Fleischhacker M., Schmidt B. Circulating nucleic acids (CNAs) and cancer-a survey. Biochim Biophys Acta 2007, 1775:181-232.
22. Shames D.S., Minna J.D., Gazdar A.F. Methods for detecting DNA methylation in tumors: from bench to bedside. Cancer Lett 2007, 251:187-198.
23. Xing M. Gene methylation in thyroid tumorigenesis. Endocrinology 2007, 148:948-953.
24. Sheils O.M., Sweeney E.C. TSH receptor status of thyroid neoplasms-TaqMan RT-PCR analysis of archival material. J Pathol 1999, 188:87-92.
25. Venkataraman G.M., Yatin M., Marcinek R., Ain K.B. Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human Na+/I-symporter gene methylation status. J Clin Endocrinol Metab 1999, 84:2449-2457.
26. Ringel M.D., Anderson J., Souza S.L., et al. Expression of the sodium iodide symporter and thyroglobulin genes are reduced in papillary thyroid cancer. Mod Pathol 2001, 14:289-296.
27. Arturi F., Russo D., Bidart J.M., Scarpelli D., Schlumberger M., Filetti S. Expression pattern of the pendrin and sodium/iodide symporter genes in human thyroid carcinoma cell lines and human thyroid tumors. Eur J Endocrinol 2001, 145:129-135.
28. Li H., Myeroff L., Smiraglia D., et al. SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers. Proc Natl Acad Sci U S A 2003, 100:8412-8417.
29. Ganapathy V., Gopal E., Miyauchi S., Prasad P.D. Biological functions of SLC5A8, a candidate tumour suppressor. Biochem Soc Trans 2005, 33:237-240.
30. Hu S., Liu D., Tufano R.P., et al. Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. Int J Cancer 2006, 119:2322-2329.
31. Twyffels L., Massart C., Golstein P.E., et al. Pendrin: the thyrocyte apical membrane iodide transporter?. Cell Physiol Biochem 2011, 28:491-496.
32. Xing M., Tokumaru Y., Wu G., Westra W.B., Ladenson P.W., Sidransky D. Hypermethylation of the Pendred syndrome gene SLC26A4 is an early event in thyroid tumorigenesis. Cancer Res 2003, 63:2312-2315.
33. Catalano M.G., Fortunati N., Boccuzzi G. Epigenetics modifications and therapeutic prospects in human thyroid cancer. Front Endocrinol 2012, 3:40.
34. Porra V., Ferraro-Peyret C., Durand C., et al. Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations in classical papillary thyroid carcinomas. J Clin Endocrinol Metab 2005, 90:3028-3035.
35. Karasarides M., Chiloeches A., Hayward R., et al. B-RAF is a therapeutic target in melanoma. Oncogene 2004, 23:6292-6298.
36. Kondo T., Ezzat S., Asa S.L. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 2006, 6:292-306.
37. Xing M. Recent advances in molecular biology of thyroid cancer and their clinical implications. Otolaryngol Clin North Am 2008, 41:1135-1146.
38. Pelizzo M.R., Boschin I.M., Barollo S., et al. BRAF analysis by fine needle aspiration biopsy of thyroid nodules improves preoperative identification of papillary thyroid carcinoma and represents a prognostic factor. A mono-institutional experience. Clin Chem Lab Med 2010, 49:325-329.
39. Giusti F., Falchetti A., Franceschelli F., Marini F., Tanini A., Brandi M.L. Thyroid cancer: current molecular perspectives. J Oncol 2010, 17. [Article ID 351679]. 10.1155/2010/351679.
40. Durante C., Puxeddu E., Ferretti E., et al. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab 2007, 92:2840-2843.
41. Nucera C., Lawler J., Parangi S. BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression. Cancer Res 2011, 71:2417-2422.
42. Martin K.J., Fournier M.V., Reddy G.P., Pardee A.B. A need for basic research on fluid-based early detection biomarkers. Cancer Res 2010, 70:5203-5206.
43. Schwarzenbach H., Hoon D.S., Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011, 11:426-437.